Merrimack Pharmaceuticals, Inc.

Equities

MACK

US5903282094

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:08:12 2024-05-09 pm EDT			5-day change	1st Jan Change
15.1 ^USD	+0.50%		+0.47%	+12.60%

01:30pm	Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024	CI
Mar. 27	Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	MT

Merrimack Pharmaceuticals, Inc. Announces to Terminate Executive Positions as of June 28, 2019

May 30, 2019 at 04:16 pm EDT

On May 29, 2019, the Board of Merrimack Pharmaceuticals, Inc. provided notice to Richard Peters, the company's President and Chief Executive Officer, and Jean M. Franchi, the company's Chief Financial Officer, that their employment with the company would be terminated as of June 28, 2019.

Latest news about Merrimack Pharmaceuticals, Inc.

Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024	07:30am	CI
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	Mar. 27	MT
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	Feb. 14	MT
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	Feb. 13	DJ
Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing	Nov. 16	MT
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to S&P Global BMI Index	23-09-18	CI
Insider Buy: Merrimack Pharmaceuticals	23-08-09	MT
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000E Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell Small Cap Completeness Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2500 Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000 Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2000 Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000 Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2000 Dynamic Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000E Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2500 Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell Small Cap Comp Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2000 Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Insider Buy: Merrimack Pharmaceuticals	23-03-22	MT
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Insider Buy: Merrimack Pharmaceuticals	23-02-01	MT

Chart Merrimack Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. It is entitled to receive payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. These payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of Onivyde for certain additional clinical indications. ONIVYDE is approved by FDA to market as a first-line treatment of metastatic adenocarcinoma on the pancreas. It is also entitled to receive payments related to its sale of anti-HER3 programs to Elevation Oncology, Inc. The Companyâs wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MERRIMACK PHARMACEUTICALS, INC.	+12.60%	218M
MODERNA, INC.	+24.69%	46.71B
LONZA GROUP AG	+48.83%	41.8B
IQVIA HOLDINGS INC.	-1.08%	41.52B
CELLTRION, INC.	-5.86%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.86%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.48%	19.26B
BIO-TECHNE CORPORATION	+2.36%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.81%	12.08B
MEDPACE HOLDINGS, INC.	+28.38%	11.98B

Other Biotechnology & Medical Research